{
    "nctId": "NCT01061359",
    "briefTitle": "Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer",
    "officialTitle": "Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer ((ANWENDUNGSBEOBACHTUNG,MOI 99056 -Neo-/Adjuvante Chemotherapie Des Prim\u00e4ren Mammakarzinoms Der Frau Mit Farmorubicin\u00ae))",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasm",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1981,
    "primaryOutcomeMeasure": "Percentage of Participants With Disease Free Survival (DFS)",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Pre- and postmenopausal female patients with histologically confirmed primary breast cancer\n\nExclusion Criteria:\n\n* Metastatic breast cancer, locally advanced or recurrent breast cancer, previous cancer history",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}